Sierra Oncology Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Sierra Oncology's estimated annual revenue is currently $9.8M per year.
- Sierra Oncology received $15.0M in venture funding in August 2018.
- Sierra Oncology's estimated revenue per employee is $119,085
- Sierra Oncology has 82 Employees.
- Sierra Oncology grew their employee count by -4% last year.
- Sierra Oncology currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Sierra Oncology?
Sierra Oncology is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. Our lead product candidate, SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). We are pursuing an innovative development plan for SRA737, which is currently being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer. SRA737-01 is intended to evaluate SRA737's potential to induce synthetic lethality as monotherapy, while the SRA737-02 is intended to evaluate the combination of SRA737 potentiated by subtherapeutic, low dose gemcitabine. Concurrently, we are conducting preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including PARP inhibitors, as well as with immuno-oncology therapeutics, that may guide a potential next wave of clinical development for our asset, possibly further broadening its therapeutic utility. We are also advancing SRA141, a potent, selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). SRA141 is currently undergoing preclinical research in preparation for an Investigational New Drug Application (IND) submission to the U.S. Food and Drug Administration (FDA).keywords:N/A
Number of Employees
Employee Growth %
Sierra Oncology News
The big shareholder groups in Sierra Oncology, Inc. (NASDAQ:SRRA) have power over the company. Institutions will often hold stock in bigger ...
Sierra Oncology, Inc. (NASDAQ:SRRA) is a stock to watch today. At current price of $0.44, the shares have already added 0.03 points (7% ...
As Biotechnology businesses, Sierra Oncology Inc. (NASDAQ:SRRA) and uniQure N.V. (NASDAQ:QURE), are affected by compare.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
Sierra Oncology Funding
|2005-10-20||$4.2M||Undisclosed||Apjohn Ventures, Grand Angles||Article|
|2018-08-23||$15.0M||Undisclosed||Silicon Valley Bank||Article|
Sierra Oncology Executive Hires
|2015-12-04||Keith Anderson||SVP Technical Operations||Article|
|2016-06-02||Christian Hassig||SVP Research||Article|